Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/306% below fair value
$165.92+0.61 (+0.37%)
Close on Nov 17, 2026Market cap $16.87BP/E 24.3Yield –
Neurocrine Biosciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Neurocrine Biosciences's price to sales ratio was 5.3× on Nov 11, 2026, against 5.7× a year earlier. Over the last 5 years it ranged from 4.3× to 8.8×, with a median of 6.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 5.3× | −0.0 |
| 2025 | Dec 31, 2025 | 5.3× | −0.9 |
| 2024 | Dec 31, 2024 | 6.2× | −1.1 |
| 2023 | Dec 29, 2023 | 7.3× | −1.0 |
| 2022 | Dec 30, 2022 | 8.3× | +0.7 |
| 2021 | Dec 31, 2021 | 7.6× | −1.0 |
| 2020 | Dec 31, 2020 | 8.6× | −6.1 |
| 2019 | Dec 31, 2019 | 14.7× | −1.0 |
| 2018 | Dec 31, 2018 | 15.6× | −86.7 |
| 2017 | Dec 29, 2017 | 102.3× | −121.8 |
| 2016 | Dec 30, 2016 | 224.1× | −21.6 |
| 2015 | Dec 31, 2015 | 245.8× | −224.9 |
| 2014 | Jul 31, 2014 | 470.6× | +444.6 |
| 2013 | Dec 31, 2013 | 26.1× | +14.3 |
| 2012 | Dec 31, 2012 | 11.7× | +5.9 |
| 2011 | Dec 30, 2011 | 5.9× | −95.4 |
| 2010 | Dec 31, 2010 | 101.3× | – |
See a number that looks wrong?